Assetmark Inc. Increases Stake in Amgen Inc.

Institutional investor adds over 14,000 shares to biotech giant's stock portfolio

Apr. 14, 2026 at 7:20am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial banking and financial machinery, conveying the complex, powerful infrastructure behind the biotech industry without using any literal currency or charts.Assetmark Inc.'s increased stake in Amgen signals institutional confidence in the biotech giant's financial strength and future growth.Thousand Oaks Today

Assetmark Inc., an investment management firm, has increased its stake in Amgen Inc. (NASDAQ: AMGN) by 6.7% during the fourth quarter of 2025. The firm now owns 228,134 shares of the medical research company's stock, valued at $74.67 million as of the most recent SEC filing.

Why it matters

Amgen is a major player in the biotechnology industry, known for its innovative drug development and strong financial performance. Institutional investors like Assetmark closely monitor and adjust their positions in Amgen, as the company's stock is considered a bellwether for the broader biotech sector.

The details

According to the SEC filing, Assetmark Inc. purchased an additional 14,341 shares of Amgen during the fourth quarter of 2025, bringing its total position to 228,134 shares. This represents a 6.7% increase in the firm's stake in the company. Assetmark's holdings in Amgen are now valued at $74.67 million, making it a significant institutional investor in the biotech firm.

  • Assetmark Inc. increased its stake in Amgen during the fourth quarter of 2025.

The players

Assetmark Inc.

An investment management firm that has increased its stake in Amgen Inc., a major biotechnology company.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

Assetmark's increased investment in Amgen reflects the firm's confidence in the biotech company's long-term growth potential. As a major institutional investor, Assetmark's actions provide insight into the broader sentiment around Amgen and the biotechnology sector.